Skip to main content
Caplight Logo









GeneSys Bio

GeneSys Bio

Private
MontefiasconeHealthcare & Life Scienceshttps://genesysbio.com/

Last Round

Grant

Jun 1, 2024

Total Funding Raised

$260,700

Momentum

Top 10%

of companies Caplight tracks

Company Overview

GeneSys Bio is a biotechnology company that develops portable, AI-driven molecular diagnostic platforms for the rapid detection of pathogens and antibiotic resistance.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Medical AI, Environmental Monitoring

Business Model

B2B

Customer Profile

Hardware + Subscription, Subscription SaaS

AI Layer

Application

Keywords

molecular diagnosticspoint-of-care testingPOCTPCR diagnostic systempathogen detectionantimicrobial stewardshipclinical decision supportdiagnostic assay kitslab-on-a-chiprapid testingmedical deviceantibiotic resistancerazor and bladeshealth IoTdigital health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GeneSys Bio Comparables

Compare GeneSys Bio with similar companies based on industry and business-model similarity.

GeneSys Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Innotive Diagnostics
85%
Llusern Scientific
84%
Detechgene
83%

GeneSys Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 1, 2024
GrantMay 1, 2024
AcceleratorJul 1, 2023

Key People

Founding team and executive leadership

Andrea Faviere

Co-founder and CEO

Founding Team

Enrico Di Oto

COO

Executive Team

GeneSys Bio Investors

Notable investors and investment history

GeneSys Bio investors
InvestorRounds
AC75 Startup AcceleratorAccelerator
CDP Venture Capital SGRAccelerator
Lazio InnovaGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 202% MoM, reaching 2.4K.

  • Jun 19, 2026

    Monthly visitors increased 57% MoM.

GeneSys Bio Filings

Explore SEC and related filing metadata, where available.

GeneSys Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about GeneSys Bio's valuation, stock price, and market status.

Is GeneSys Bio a public or private company?

GeneSys Bio is a private company.

What is the current stock price of GeneSys Bio?

GeneSys Bio is a private company with no public stock price. Caplight tracks GeneSys Bio's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is GeneSys Bio worth (valuation)?

Valuation information for GeneSys Bio is not publicly available.

Can I buy GeneSys Bio stock?

GeneSys Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was GeneSys Bio's last funding round?

GeneSys Bio's most recent funding round was Grant on June 1, 2024.

Who are the main investors in GeneSys Bio?

Key investors in GeneSys Bio include AC75 Startup Accelerator, CDP Venture Capital SGR, Lazio Innova.

Will GeneSys Bio IPO soon?

No public IPO plans have been announced for GeneSys Bio.

How can I track GeneSys Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GeneSys Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMontefiascone
Employee Range5
Year Founded2023
Last FundingJun 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?